New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
10:25 EDTFLDM, FLDM, ILMN, ILMN, ONT, ONT, PACB, PACB, TMO, TMOLeerink's life science tools analyst holds an analyst/industry conference call
Life Science Tools & Diagnostics Analyst Leonard provides perspectives on new advances in DNA sequencing, particularly Illumina's new sequencing instruments, the HiSeqXTen and NextSeq 500, as well as provide an update on Pacific Biosciences, on an Analyst/Industry conference call to be held on January 17 at 11 am.
News For FLDM;ILMN;ONT;PACB;TMO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
09:48 EDTTMOThermo Fisher management to meet with Leerink
Subscribe for More Information
May 26, 2015
09:44 EDTILMNIllumina participates in a conference call with JPMorgan
Subscribe for More Information
May 20, 2015
08:01 EDTTMOThermo Fisher to host analyst meeting
Subscribe for More Information
May 19, 2015
09:18 EDTILMN, TMOBofA/Merrill life sciences analysts hold an analyst/industry conference call
Analysts, along with Nancy J. Kelley, a nationally recognized executive and lawyer who has championed the field of Synthetic/Engineering Biology in the U.S., discuss what Synthetic Biology is and whether it will disrupt the Healthcare landscape and how Synthetic Biologic-based products would be regulated on an Analyst/Industry conference call to be held on May 19 at 2 pm.
09:08 EDTTMO3D Systems enters reseller agreement with Thermo Fisher
Subscribe for More Information
May 18, 2015
16:07 EDTILMNIllumina files new patent infringement suit against Roche unit
Subscribe for More Information
06:38 EDTFLDMFluidigm shares offer attractive entry point, says Leerink
Leerink believes the current share of Fluidigm represents an attractive entry point ahead of the company's new product launches. The firm thinks Fluidigm is well positioned to benefit from the growth in single cell analysis. It keeps an Outperform rating on the name with a $45 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use